Should I Buy MOH? MOH 2026 Analysis

Should You Buy Molina Healthcare Inc (MOH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

184.930

1 Day change

-1.11%

52 Week Range

359.970

Analysis Updated At

2026/01/26

Molina Healthcare Inc. (MOH) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. While the stock has shown some recent price appreciation and analysts have raised price targets, the company's financial performance in the latest quarter shows significant declines in net income, EPS, and gross margin. Additionally, technical indicators suggest the stock is overbought, and options data indicates bearish sentiment. Given these factors, it is prudent to hold off on buying until there is clearer evidence of sustained growth or a more favorable entry point.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 84.285, signaling the stock is overbought. Moving averages are converging, suggesting indecision in the trend. Key resistance levels are at R1: 199.648 and R2: 205.381, with the stock currently trading near these levels, which could act as a barrier to further upward movement.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts have raised price targets recently, with some projecting significant upside (e.g., Bernstein at $224 and Nephron Research at $250).
Moon Capital Management initiated a position at $160, reflecting confidence in the company's future.
The White House's 'Great Healthcare Plan' could provide long-term tailwinds for the healthcare sector.

Neutral/Negative Catalysts

Financial performance in Q3 2025 was weak, with net income dropping by -75.77% YoY and EPS declining by -73.45% YoY.
Options data shows bearish sentiment, with a high option volume put-call ratio of 2.
RSI indicates the stock is overbought, suggesting a potential pullback.
Analysts have expressed concerns about Medicaid uncertainties and legislative risks in 2026.

Financial Performance

In Q3 2025, revenue increased by 11.00% YoY to $11.477 billion. However, net income dropped significantly by -75.77% YoY to $79 million, EPS fell by -73.45% YoY to $1.5, and gross margin declined by -24.25% YoY to 12.09%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have mixed views on Molina Healthcare. Several firms, including Bernstein and Mizuho, have raised price targets and maintain Outperform ratings, citing potential sector recovery and attractive entry points. However, others like Truist and Barclays remain cautious, with concerns about Medicaid uncertainties and legislative risks. The average sentiment leans positive but with notable risks.

14 Analyst Rating

Wall Street analysts forecast MOH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOH is 180.85 USD with a low forecast of 155 USD and a high forecast of 250 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

9 Hold

2 Sell

Hold

Current: 187.000

Low

155

Averages

180.85

High

250

Current: 187.000

Low

155

Averages

180.85

High

250

Mizuho

Ann Hynes

Outperform

maintain

$200 -> $220

AI Analysis

2026-01-09

Reason

Mizuho

Ann Hynes

Price Target

$200 -> $220

AI Analysis

2026-01-09

maintain

Outperform

Reason

Mizuho analyst Ann Hynes raised the firm's price target on Molina Healthcare to $220 from $200 and keeps an Outperform rating on the shares. The firm updated targets in the healthcare facilities and managed care group as part of a Q4 preview. Mizuho's physician survey indicated healthcare utilization growth trends decelerated sequentially despite easier year-over-year comps, which could indicate trend is peaking, the analyst tells investors in a research note.

Wells Fargo

Stephen Baxter

Overweight

maintain

$165 -> $208

2026-01-07

Reason

Wells Fargo

Stephen Baxter

Price Target

$165 -> $208

2026-01-07

maintain

Overweight

Reason

Wells Fargo analyst Stephen Baxter raised the firm's price target on Molina Healthcare to $208 from $165 and keeps an Overweight rating on the shares. For managed care organizations, the firm is most constructive on Medicare Advantage with uncertainty high for Medicaid/Exchanges. Wells sees a more difficult backdrop for hospitals in 2026 as post-COVID tailwinds wane and legislative risks near. Distributor debate remains revisions vs. multiples.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MOH

Unlock Now

MOH Should I Buy

MOH Should I Buy

Should You Buy Molina Healthcare Inc (MOH) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch